9 results about "Cerebral vasospasm" patented technology

The present invention discloses the application of Chinese medicine Polygonum aviculare in the preparation of drugs for preventing and treating stroke. It relates to the field of biomedicine technology. The present invention shows that Chinese medicine Polygonum aviculare can significantly reduce the brain water content and brain index of experimental animals, and can treat brain edema. The drug has the effects of promoting blood circulation and removing blood stasis, can eliminate cerebral vascular blockage and inflammation, resist cerebral vasospasm, maintain normal cerebral vascular function, regulate normal permeability of brain barrier, promote angiogenesis, promote brain nerve function repair and regeneration, and greatly restore the nerve damage and behavioral ability of patients with cerebral stroke. Chinese medicine Polygonum aviculare can be dialectically used for the prevention and treatment of various courses of ischemic stroke and hemorrhagic stroke. The present invention not only provides a new application of Chinese medicine Polygonum aviculare, but also provides a new drug for preventing and treating ischemic stroke and hemorrhagic stroke.

Prodrugs of neurosteroid analogs are disclosed. Pharmaceutical formulations containing the prodrugs are also disclosed, Additionally, methods of treating a condition, disorder, or disease using the prodrugs or their pharmaceutical formulations are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, CNS injury, concussion, traumatic brain injury, depression, postpartum depression, epilepsy, seizure disorder, and neurodegenerative disease.

The present disclosure provides a nose-to-brain delivery formulation of nimodipine. The present disclosure also provides a method of preventing or treating ischemic disorders in a patient, in particular cerebral ischemic disorders, cerebral vasospasm due to subarachnoid hemorrhage, and sudden deafness, comprising administering said nimodipine nose-to-brain delivery formulation. The present disclosure also provides a composition, comprising a nose-to-brain delivery formulation of nimodipine and pharmaceutically acceptable excipient.

The invention discloses application of a (+)-ABX-CL compound in preparation of an endothelin receptor inhibitor in the field of pharmaceutical application. Basic research is carried out for finding effective medicines for treating diseases such as tumors, heart failure, atherosclerosis, cerebral vasospasm and the like, a new lead compound is found through in-vivo and in-vitro screening, and a basis is provided for finding new medicines.

The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating cerebral inflammation and associated sequelae thereof including cerebral vasospasm. In one embodiment, a method for treating cerebral vasospasm in a patient comprises the step of administering to the patient a PD-1 agonist, wherein a blood sample obtained from the patient comprises elevated PD-1 expression on monocytes relative to a control.

The invention is directed to a method and apparatus for early warning of cerebral vasospasm after subarachnoid hemorrhage using brain imaging equipment to identify blood leakage within the subarachnoid space to detect brain zones with increased risk of cerebral vasospasm.

Disclosed are neurosteroids and prodrugs thereof. Pharmaceutical formulations containing the neurosteroids and prodrugs are also disclosed. Additionally, methods of treating a condition, disorder, or disease using the neurosteroids, prodrugs, or pharmaceutical formulations are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, CNS injury, concussion, traumatic brain injury, depression, postpartum depression, epilepsy, seizure disorder, essential tremor, fragile X syndrome, and neurodegenerative disease.

Compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM / DARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and / or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.

Prodrugs of neurosteroid analogs are disclosed. Pharmaceutical formulations containing the prodrugs are also disclosed. Additionally, methods of treating a condition, disorder, or disease using the prodrugs or their pharmaceutical formulations are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, CNS injury, concussion, traumatic brain injury, depression, postpartum depression, epilepsy, seizure disorder, essential tremor, fragile X syndrome, and neurodegenerative disease.